Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Pharma Journalist Magazine
by Pharma Journalist
2d ago
Biogen Inc. and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments. HI-Bio’s lead asset, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to selectively deplete CD38+ cells including plasma cells and natural killer, or NK, c ..read more
Visit website
Sandoz receives European Commission approval for Wyost and Jubbonti, the first and only biosimilars of denosumab in Europe
Pharma Journalist Magazine
by Pharma Journalist
2d ago
Sandoz, the global leader in generic and biosimilar medicines, announced that the European Commission (EC) has granted marketing authorization for Wyost(denosumab) and Jubbonti (denosumab), the first and only biosimilar versions of reference medicines Xgeva and Prolia in Europe. Wyost is approved for the treatment of cancer-related bone disease.1 Jubbonti is approved to treat osteoporosis. These are key biosimilar value drivers for the company over the mid-term and their approval is a major step in advancing the Sandoz growth strategy. We expect to launch from November 2025 onwards. Claire D ..read more
Visit website
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Pharma Journalist Magazine
by Pharma Journalist
2d ago
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scal ..read more
Visit website
AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program
Pharma Journalist Magazine
by Pharma Journalist
2d ago
AltruBio Inc., a clinical stage biotechnology company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, announced an oversubscribed Series B financing of up to $225 million. AltruBio plans to use the proceeds of the financing to advance the clinical development of the Company’s first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. The funds will be used to support ongoing and planned Phase 2 clinical trials in ulcerative colitis (UC), one of many immunological disorders where the me ..read more
Visit website
Genmab Completes Acquisition of ProfoundBio
Pharma Journalist Magazine
by Pharma Journalist
2d ago
Genmab A/S announced that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses). With the completion of this strategic transaction, we are excited to welcome our new colleagues and their expertise in developing next-generation antibody-drug conjugates to our exceptionally talented R&D team,” said Jan van de Winkel ..read more
Visit website
AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore
Pharma Journalist Magazine
by Pharma Journalist
2d ago
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises ..read more
Visit website
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia & Xgeva in the U.S., Europe and UK
Pharma Journalist Magazine
by Pharma Journalist
2d ago
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). The collaboration combines Dr. Reddy’s global commercial presence with Alvotech’s proven capabilities in developing biosimilars for markets worldwide. Prolia and Xgeva are indicated ..read more
Visit website
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Pharma Journalist Magazine
by Pharma Journalist
2d ago
Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. “We are pleased that the FDA granted Breakthrough Therapy Designation for ..read more
Visit website
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Pharma Journalist Magazine
by Pharma Journalist
1w ago
Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt’s cutting-edge clinical capabilities with Fulgent’s groundbreaking nanotherapeutics and genomics platforms in an effort to accelerate the development of personalized cancer therapies. Under the ..read more
Visit website
Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design
Pharma Journalist Magazine
by Pharma Journalist
1w ago
Nabla Bio, pioneers in generative protein design, announced the close of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZeneca, Bristol Myers Squibb Company and Takeda, worth more than $550 million in upfront and milestone payments, plus royalties. Nabla develops integrated AI and wet-lab technologies that enable atomically precise drug design and high-throughput measurement of drug function, with an initial focus on antibodies targeting multipass membrane proteins, including for example, G prote ..read more
Visit website

Follow Pharma Journalist Magazine on FeedSpot

Continue with Google
Continue with Apple
OR